Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | TK2 | O00142 | 2/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65560 | 0.84 | TK1 (0.47) | TK1 | |
| SCHEMBL65561 | 0.82 | ALDH1A1 (0.41) | LMNATK2 | |
| SCHEMBL67327 | 0.80 | LMNA (0.47) | LMNASMN1; SMN2TK1 | |
| SCHEMBL8356495 | 0.76 | TK1 (0.47) | LMNATSHRPMP22TK1 | |
| SCHEMBL8996145 | 0.73 | TK1 (0.51) | LMNATSHRPMP22TK1 | |
| SCHEMBL933232 | 0.70 | ALDH1A1 (0.41) | LMNATK2 | |
| SCHEMBL932884 | 0.70 | TK1 (0.45) | LMNATSHRPMP22TK1 | |
| SCHEMBL933229 | 0.69 | TK1 (0.47) | TK1 | |
| SCHEMBL933231 | 0.69 | TK1 (0.47) | TK1 | |
| SCHEMBL2056628 | 0.69 | LMNA (0.51) | LMNATSHRPMP22TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139911-A1 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| EP-1855694-B1 | ANTISENSE COMPOSITION FOR TREATING MUSCLE ATROPHY | SAREPTA THERAPEUTICS INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10626396-B2 | Antisense composition and method for treating muscle atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10479996-B2 | Antisense antiviral compound and method for treating ss/RNA viral infection | SAREPTA THERAPEUTICS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180327749-A1 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-11-15 | — | — | US | disclosed |
| US-10006031-B2 | Antisense composition and method for treating muscle atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-9982261-B2 | Antisense antiviral compounds and methods for treating a filovirus infection | SAREPTA THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170306323-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-10-26 | — | — | US | disclosed |
| EP-3205342-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | Sarepta Therapeutics, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2603220-B1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | SAREPTA THERAPEUTICS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-1668145-A2 | SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION | Avi Biopharma, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1654363-A2 | OLIGONUCLEOTIDE ANALOG AND METHOD FOR TREATING FLAVIVIRUS INFECTIONS | Avi Biopharma, Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2006033933-A2 | ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING SSRNA VIRAL INFECTION | AVI BIOPHARMA, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063150-A1 | Antisense antiviral compound and method for treating ssRNA viral infection | SAREPTA THERAPEUTICS, INC. | 2006-03-23 | — | — | US | disclosed |
| US-20050261249-A1 | Antisense composition and method for treating cancer | AVI BIOPHARMA, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005089247-A2 | ANTISENSE COMPOSITION AND METHOD FOR TREATING CANCER | AVI BIOPHARMA, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050171044-A1 | Oligonucleotide compound and method for treating nidovirus infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-04 | — | — | US | disclosed |
| US-20050096291-A1 | Oligonucleotide analog and method for treating flavivirus infections | SAREPTA THERAPEUTICS, INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005030800-A2 | OLIGONUCLEOTIDE ANALOG AND METHOD FOR TREATING FLAVIVIRUS INFECTIONS | AVI BIOPHARMA, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005013905-A2 | SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION | AVI BIOPHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170306323-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | HNRNPU, MED25, SSU72 | LMNA 1275/4885SMN1; SMN2 262/4885TSHR 3254/4885 |
| US-20050171044-A1 | Oligonucleotide compound and method for treating nidovirus infections | RNGTT, NSUN2, FBL | LMNA 806/4885SMN1; SMN2 668/4885TSHR 3384/4885 |
| US-10006031-B2 | Antisense composition and method for treating muscle atrophy | MYOF, TNNC1, MTPN | LMNA 549/4885SMN1; SMN2 41/4885TSHR 1899/4885 |
| US-10479996-B2 | Antisense antiviral compound and method for treating ss/RNA viral infection | SARS1, SSU72, RNGTT | LMNA 2372/4885SMN1; SMN2 473/4885TSHR 1607/4885 |
| US-10626396-B2 | Antisense composition and method for treating muscle atrophy | MYOF, TNNC1, MTPN | LMNA 549/4885SMN1; SMN2 41/4885TSHR 1899/4885 |
| US-20180327749-A1 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY | MYOF, TNNC1, MTPN | LMNA 549/4885SMN1; SMN2 41/4885TSHR 1899/4885 |
| US-20060063150-A1 | Antisense antiviral compound and method for treating ssRNA viral infection | SARS1, RNGTT, EIF2AK2 | LMNA 1351/4885SMN1; SMN2 778/4885TSHR 1763/4885 |
| US-20210139911-A1 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY | MYOF, TNNC1, MTPN | LMNA 549/4885SMN1; SMN2 41/4885TSHR 1899/4885 |
| US-20050096291-A1 | Oligonucleotide analog and method for treating flavivirus infections | NSUN2, RNGTT, ADAR | LMNA 357/4885SMN1; SMN2 823/4885TSHR 890/4885 |
| US-20050261249-A1 | Antisense composition and method for treating cancer | RNASE1, HNRNPH3, HNRNPD | LMNA 622/4885SMN1; SMN2 1068/4885TSHR 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.